Sagimet Biosciences Inc. reported a solid liquidity position with over $100 million in cash, enabling continued clinical development of its lead FASN inhibitor, denifanstat, for metabolic dysfunction-associated steatohepatitis (MASH) and acne. The recent quarter highlighted sustained R&D focus with no revenues, typical for a clinical-stage biopharma. Sagimet’s differentiation lies in its selective oral FASN inhibitors and strategic partnership in Greater China. Key growth drivers include late-stage clinical data and potential combination therapies targeting advanced fibrosis. Risks center on inherent clinical trial uncertainties and the need for ongoing capital to sustain operations.